Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%

MT Newswires Live

May 26

Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.

The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.

The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.

Shares of the pharma manufacturer were down over 3% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2538121869"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538121869\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538121869?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-26 13:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538121869","market":"fut","top_or_hot":-1,"title":"Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.</p><p>The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.</p><p>The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.</p><p>Shares of the pharma manufacturer were down over 3% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-26 13:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.</p><p>The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.</p><p>The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.</p><p>Shares of the pharma manufacturer were down over 3% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2538121869","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538121869","pubTimestamp":1748237333,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Grand Pharmaceutical Group  said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.Shares of the pharma manufacturer were down over 3% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00512":"远大医药"},"translate_title":"远大医药治疗蠕形螨睑缘炎在澳门获批；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9},"content_text":"Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.Shares of the pharma manufacturer were down over 3% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}